This study demonstrates the quantitative characteristics of the first patient-reported outcome (PRO) tool developed for patients with nontransfusion-dependent β-thalassemia (NTDT), the NTDT-PRO © . A multicenter validation study was performed over 24 weeks, involving 48 patients from Italy, Lebanon, Greece, and Thailand. Most patients were female (68.8%), with a median age of 34.5 years (range, 18-52); 66.7% were diagnosed with β-thalassemia intermedia, and median time since diagnosis was 22 years (range, 0-43). The NTDT-PRO comprises 6 items across 2 domains (Tiredness/Weakness and Shortness of Breath [SoB]), and was valid and reliable, with good consistency. At baseline, most patients reported symptoms as present via the NTDT-PRO, and were highly compliant, ≥90% completing the NTDT-PRO tool. In a pairwise correlation analysis, all items were positively correlated. Correlations between NTDT-PRO and existing tools-36-Item Short Form Health Survey version 2 (SF-36v2) and Functional Assessment of Cancer Therapy-Anemia (FACT-An)-were assessed at weeks 1, 3, and 12; robust correlations were seen between SoB and SF-36v2-Vitality (r s = −0.53), and between SoB and Fact-An-Fatigue Experience (r s = −0.66) at week 1. Internal consistency was high for both Tiredness/Weakness (Cronbach alpha, 0.91) and SoB (Spearman-Brown coefficient, 0.78); intraclass correlation coefficients were high (Tiredness/Weakness, 0.88 and 0.97; SoB, 0.92 and 0.98), demonstrating stability. Further studies are required to fully support the validity of this tool, this study demonstrated the usefulness of the NTDT-PRO in the clinical setting and for longitudinal clinical research, particularly in trials where patient health-related quality of life is expected to change. The objective of the present study was to validate the NTDT-PRO against existing HRQoL tools (SF-36v2 and FACT-An) in patients
| INTRODUCTION
The hereditary blood disorder β-thalassemia affects approximately 1.5% of the global population. 1 In 2008, the World Health Organization estimated that more than 40 000 children are born annually with β-thalassemia, of which over 20 000 are in Southeast Asia. 2 More recent estimates from Europe suggest there are approximately 7000 patients in Italy (0.012% of a total population of approximately 60 million) and 3241 patients in Greece (0.029% of a total population of 11 million) with thalassemias. 3 Modern patterns of increased migration have resulted in thalassemias becoming widespread in other regions, 4 as illustrated by a report from the Centers for Disease Control that reported that 27% of people with nontransfusion-dependent β-thalassemia (NTDT) in North America were born overseas. 5 Increasing global access to health care and the resultant increase in life expectancy of patients with thalassemias has intensified efforts † Former employee of Celgene Corporation.
to understand how this condition affects health-related quality of life (HRQoL). Although disease burden varies according to whether a patient has NTDT or transfusion-dependent thalassemia (TDT), the impact on HRQoL and general well-being is significant. 6, 7 At present, the main HRQoL patient-reported outcome (PRO) tools used in thalassemias are the 36-Item Short Form Health Survey version 2 (SF-36v2) and the Functional Assessment of Cancer Therapy-Anemia (FACT-An) tools. These tools, particularly the SF-36v2, are not disease specific and may include symptoms beyond those that thalassemia patients would typically experience.
The majority of studies that investigate HRQoL using the SF36v2 in thalassemias focus on TDT, for example, in Italy 8 and Greece. 9 However, the SF-36v2 was used in a longitudinal study of 264 patients with TDT and NTDT from the United States, Canada, and the United Kingdom, and found that HRQoL was significantly lower in this population compared with US norms, and interestingly, saw a higher HRQoL associated with being transfused, 10 the presence or severity of the following symptoms using a numerical rating scale ranging from 0 ("absent/minimal") to 10 ("extreme"): Tiredness with or without Physical Activity, Weakness with or without Physical Activity, and Shortness of Breath (SoB) with or without Physical Activity. These items were selected as a basis for the NTDT-PRO following expert panel discussion and patient interviews.
The objective of the present study was to validate the NTDT-PRO against existing HRQoL tools (SF-36v2 and FACT-An) in patients
with NTDT, and demonstrate the sensitivity and score reliability over time of the NTDT-PRO when used in patients with NTDT. The NTDT-PRO was evaluated in a prospective observational study with no protocol-driven treatment intervention (NCT02626689).
Although the observational study included both TDT (n = 52) and NTDT (n = 50) patients, only NTDT patients were included in this Changes in patient health status since the start of the study were also assessed using the Patient Global Impression of Change (PGIC) scale once every 3 weeks.
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Three weeks was selected as a testing interval for this study to match the dosing regimen for luspatercept, a novel therapy under development for TDT and NTDT.
| Measures and procedures
The NTDT-PRO was designed to capture thalassemia-related symptoms over the previous 24 hr using six symptom-specific items (Appendix in Supporting Information). An additional item was included in the NTDT-PRO for the purposes of validation, to assess the overall severity of the patients' thalassemia symptoms in the previous 24 hr on a numerical scale ranging from 0 ("no symptoms") to 10 ("very severe symptoms"). Item scores were summarized as the mean of nonmissing values over a 7-day period; if entries were missing for ≥4 days in any 7-day period, the weekly average was considered missing. For the two domains, Tiredness/Weakness and SoB, the mean and sum of items in the domain were reported.
All HRQoL questionnaires (NTDT-PRO, SF-36v2, and FACT-An)
were administered in the local language (English, Thai, Greek, Arabic, or Italian, as appropriate). For the SF-36v2 and FACT-An, the most recently validated local language versions were used, available from Optum and FACIT.org, respectively. For the NTDT-PRO, the original English version was reviewed for translation accuracy by local thalassemia experts who were involved in the study (MDC for Italian, AT for Arabic, AK for Greek, and VV for Thai; translations available on request).
Data from patients who reported "no change" (ie, a score of 4 on a 0-10 scale) on the PGIC during weeks 3 and 12 of the study were used to assess test-retest reliability.
Patients with both a valid week of daily data collection at baseline (defined as ≥4 complete diary entries in the 7-day period) and data for ≥1 questionnaire (SF-36v2, FACT-An) at baseline were included in the analysis.
| Statistical analysis
Quantitative data, including weekly averaged NTDT-PRO items, were summarized using descriptive statistics.
| Internal consistency and validity
Internal consistency was assessed by calculating the Spearman rank correlation coefficient to evaluate the strength and direction of a relationship between all NTDT-PRO items.
To examine internal validity, reliability was tested using the Cronbach alpha coefficient for the Tiredness/Weakness domain score.
As SoB contained only two variables, the Spearman-Brown coefficient was calculated to determine the consistency of this measure.
| Validity
To 
| Stability over time and sensitivity to change
To evaluate the stability of weekly averaged NTDT-PRO items and domain scores, test-retest reliability was assessed by calculating the intraclass correlation coefficient (ICC) over 2 intervals (weeks 1-3 and weeks 9-12) in patients who reported no change in their overall β-thalassemia symptoms at week 3 and 12, as measured by PGIC score.
Sensitivity to change was assessed by examining changes in domain scores between weeks 1 and 24 in three groups identified as improved, no change, or worse based on PGIC score at week 24.
However, as this study was observational and did not involve an intervention, significant changes were not anticipated.
Correlations between 0.20 and 0.39 were defined as "weak,"
correlations between 0.40 and 0.59 as "moderate," correlations between 0.60 and 0.79 as "strong," and those ≥0.80 were defined as "very strong." Significance was defined as P < .05. Table 1 .
The majority of patients were female (68.8%), with a median age of 34.5 years (range, 18-52).
During the course of the study, 7 patients (15.0%) received RBC transfusions.
| NTDT-PRO distribution characteristics
NTDT-PRO item and domain scores are detailed in Table S1 in the Supporting Information. Of the 48 patients included in the study, a median of 37 patients (range, 30-48) completed the NTDT-PRO and contributed data each week (≥4/7 days). The individual items with the highest scores across the 24 weeks of testing were Tiredness with Physical Activity (TiredPA) (range, 0-10.00) and Weakness with Physical Activity (WeakPA) (range, 0-10.00); the lowest scores were seen for SoB without Physical Activity (SoBNA) (range, 0-7.83).
| Internal consistency of NTDT-PRO
Spearman rank correlations between NTDT-PRO items are shown in Table S2 Table 2 ). The correlation within the SoB domain was also strong (Spearman-Brown coefficient, 0.78). (Table 3 ). An exploratory factor analysis was used to explore item groupings, which led to the combining of data from the Tiredness and Weakness domains. The structural coefficients for Known groups validity analysis with comorbidities showed that as the number of comorbidities increased from 1 to 4, the ratings of severity for the Tiredness/Weakness, SoB items and both domain scores increased. When the number of comorbidities was greater than 4, the severity decreased, and in some cases, below the level of severity for 0 comorbidities (eg, TiredPA, TiredNA, WeakNA, SoB domain) (data not shown).
| Stability over time and sensitivity to change
The stability of the NTDT-PRO was assessed by looking at test-retest reliability over weeks 1-3 (n = 32) and weeks 9-12 (n = 21) for the 2 NTDT-PRO domain scores in patients who reported no change by PGIC (Table 4) . ICCs were high for Tiredness/Weakness (0.88 and 0.97) and SoB (0.92 and 0.98) at all time points studied, and the average difference in scores between weeks 1 and 3 (Tiredness/Weakness: 0.08; SoB: −0.06), and weeks 9 and 12 (Tiredness/Weakness: 0.01; SoB: −0.05) was small.
To assess the ability of the NTDT-PRO to detect change in health status, PGIC responses were examined. Across the 24 weeks of the study, the majority of patients (17 patients; 63%) reported no change in PGIC score; 5 patients (19%) reported a worsening, and 5 patients (19%) an improvement of the PGIC score. However, as expected in this observational, noninterventional study, no significant change in NTDT-PRO domain score from weeks 1 to 24 was observed, regardless of change in PGIC score (data not shown).
| DISCUSSION
Patients with NTDT experience symptoms that negatively impact their HRQoL, and there is a paucity of specific tools to quantify this in these patients. This study reports the multicenter validation of a novel disease-specific PRO tool for patients with NTDT, the NTDT-PRO.
The NTDT-PRO was developed using concept-elicitation interviews, interview discussions, cognitive interviews, and clinical input. Concept elicitation identified 11 symptoms from which 9 were selected for inclusion in the questionnaire. the NTDT-PRO measures that same concept in the corresponding domains/scales of the SF-36v2 and FACT-An tools.
The strength of these correlations suggests that tiredness and weakness, and shortness of breath, as assessed by the NTDT-PRO, represent proximal aspects of the NTDT disease experience rather than HRQoL per se.
Patient PGIC scores were assessed at baseline and throughout the study to provide an anchor for the data set and allow identification of clinically important responders. While the majority (63%) of patients reported no change in PGIC, several patients reported either improvement (19%) or worsening (19%) of disease by PGIC. As this study was designed as an observational, noninterventional study, significant changes were not expected in PGIC or NTDT-PRO scores.
The NTDT-PRO tool was developed in a population of patients with a diagnosis of nontransfusion-dependent β-thalassemia confirmed by chart review; it is likely that it would yield similar results in patients with nontransfusion-dependent α-thalassemia; however, further research would be required before this tool can be recommended for use in other NTDT populations. This study did not assess the responsiveness of the NTDT-PRO to treatment, and future studies to validate this tool in an interventional setting will provide further insight into the sensitivity to change of the NTDT-PRO. The ecological validity, that is, the generalizability of the tool to a real-world setting, such as community-based centers versus academic centers, has also not been assessed. Further validation of the NTDT-PRO in these realworld settings will be important to increase the utility of the tool.
This study supports the validity of the NTDT-PRO tool as appropriate and stable for assessment of key symptoms in patients with NTDT. The NTDT-PRO tool takes under 5 min to complete, less than the time required both for the SF-36v2 and for the FACT-An (around 10 min for each). Moreover, this score provides a novel, diseasespecific tool focusing on symptoms that were identified as significant to patients with NTDT, both according to physician insight and from self-report of patient experience. The NTDT-PRO could, therefore, be 
